Profiling drug-like properties in discovery research

Current Opinion in Chemical Biology

Volumn 7, Issue 3, 2003, Pages 402-408

  Di, Li ^a   Kerns, Edward H ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 BENZYLOXY 4 (TRIFLUOROMETHYL)COUMARIN; COUMARIN DERIVATIVE; CYTOCHROME P450 INHIBITOR; UNCLASSIFIED DRUG;

ACCURACY; BLOOD BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; COMPUTER MODEL; DRUG DESIGN; DRUG DETERMINATION; DRUG PENETRATION; DRUG RESEARCH; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; INTESTINE MUCOSA PERMEABILITY; LIPOPHILICITY; LIVER; MEMBRANE PERMEABILITY; PLASMA; REVIEW; SIDE EFFECT;

EID: 0037523454     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(03)00055-3     Document Type: Review

References (55)

1. Venkatesh S., Lipper R.A. Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 89:2000;145-154 A key milestone that illuminates the contributions that development experience can make to discovery, to improve candidate readiness for development.
2. Smith D.A. High-throughput screening - brain versus brawn. Ernst Schering Research Foundation Workshop. 37:2002;203-212 An excellent article on issues and challenges facing today's drug discovery.
3. Kerns E.H. High throughput physicochemical profiling for drug discovery. J. Pharm. Sci. 90:2001;1838-1858 Review of current high-throughput profiling assays for physicochemical properties.
4. Kerns E.H., Di L. Multivariate pharmaceutical profiling for drug discovery. Curr. Topics Med. Chem. 2:2002;87-98.
5. Yan Z., Caldwell G.W. Metabolism profiling and cytochrome P450 inhibition & induction in drug discovery. Curr. Topics Med. Chem. 1:2001;403-425 A thorough summary of current strategies in pharmacokinetics, toxicokinetics, drug metabolism, and drug-drug interaction for profiling drug discovery candidates.
6. Rodrigues A.D., Lin J.H. Screening of drug candidates for their drug-drug interaction potential. Curr. Opin. Chem. Biol. 5:2001;396-401 Key insights on the motivation, procedures and application of drug-drug interaction monitoring in drug discovery.
7. van de Waterbeemd H., Smith D.A., Beaumont K., Walker D.K. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 44:2001;1313-1333 The authors introduce the concept of property-based design and provide a broad-ranging discussions on designing drugs with optimal drug-like properties.
8. McGovern S.L., Caselli E., Grigorieff N., Shoichet B.K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45:2002;1712-1722.
9. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharm. Tox. Methods. 44:2000;235-249 Outstanding article on the correlation of lead-generation strategies (HTS and rational design) with their effects on the solubility and permeability of discovery candidates.
10. Lipinski C.A. Avoiding investment in doomed drugs. Curr. Drug Disc. April:2001;17-19.
11. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 46:2001;3-26 Landmark article on solubility, its effects on drug discovery research, and the highly effective 'rule of 5' for drug-like properties.
12. Bevan C.D., Lloyd R.S. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal. Chem. 72:2000;1781-1787.
13. Avdeef A. Physicochemical profiling (solubility, permeability and charge state). Curr. Topics Med. Chem. 1:2001;277-351 A detailed treatise on the fundamentals of key physicochemical properties, how these properties affect drug interaction with biological systems, and drug absorption.
14. Pan L., Ho Q., Tsutsui K., Takahashi L. Comparison of chromatographic and spectroscopic methods used to rank compounds for aqueous solubility. J. Pharm. Sci. 90:2001;521-529.
15. Chen T.M., Shen H., Zhu C. Evaluation of method for high throughput solubility determination using a multi-wavelength UV plate reader. Comb. Chem. High Throughput Screen. 5:2002;575-581.
16. Artursson P., Palm K., Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46:2001;27-43.
17. Irvine J.D., Takahashi L., Lockhart K., Cheong J., Tolan J.W., Selick H.E., Grove J.R. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88:1999;28-33.
18. Otis K.W., Avery M.L., Broward-Partin S.M., Hansen D.K., Behlow H.W. Jr., Scott D.O., Thompson T.N. Evaluation of BBMEC model for screening the CNS permeability of drugs. J. Pharm. Tox. Methods. 45:2001;71-77.
19. Kansy M., Senner F., Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41:1998;1007-1010.
20. Wohnsland F., Faller B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J. Med. Chem. 44:2001;923-930.
21. Sugano K., Takata N., Machida M., Saitoh K. Prediction of total passive permeation using bio-mimetic artificial membrane permeability and paracellular pathway model. J. Pharm. Sci. Tech. Japan. 62:2002;241.
22. Zhu C., Jiang L., Chen T.M., Hwang K.K. A comparative study of artificial permeability assay for high throughput profiling of drug absorption potential. Eur. J. Med. Chem. 37:2002;399-407.
23. Di L, Kerns EH, Fan K, McConnell OJ, Carter G: High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 2003, in press.
24. Benet L.Z., Cummins C.L. The drug efflux-metabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev. 50(Suppl 1):2001;S3-11.
25. Polli J.W., Wring S.A., Humphreys J.E., Huang L., Morgan J.B., Webster L.O., Serabjit-Singh C.S. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharm. Exp. Ther. 299:2001;620-628.
26. Penzotti J.E., Lamb M.L., Evensen E., Grootenhuis D.J. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J. Med. Chem. 45:2002;1737-1740.
27. van de Waterbeemd H., Smith D.A., Jones B.C. Lipophilicity in PK design: methyl ethyl, futile. J. Computer-Aided Mol. Design. 15:2001;273-286.
28. Comer JEA: High throughput measurement of Log D and pKa. In Drug Bioavailability. Estimation of Solubility, Permeability and Absorption. Edited by van de Waterbeemd H, Lennernas H, Artursson P. Weinheim: Wiley-VCH; in press.
29. Hitzel L., Watt A.P., Locker K.L. An increased throughput method for the determination of partition coefficients. Pharm. Res. 17:2000;1389-1395.
30. Gulyaeva N., Zaslavsky A., Lechner P., Chlenov M., Chait A., Zaslavsky B. Relative hydrophobicity and lipophilicity of β-blockers and related compounds as measured by aqueous two-phase partitioning, octanol-buffer partitioning, and HPLC. Eur. J. Pharm. Sci. 17:2002;81-93.
31. Lombardo F., Shalaeva M.Y., Tupper K.A., Gao F. ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. J. Med. Chem. 44:2001;2490-2497.
32. Valko K., Du C.M., Bevan C., Reynolds D.P., Abraham M.H. Rapid method for the estimation of octanol/water partition coefficient (log P(oct)) from gradient RP-HPLC retention and a hydrogen bond acidity term (Σα2H). Curr. Med. Chem. 8:2001;1137-1146.
33. ow) by microemulsion electrokinetic chromatography. J. Chromatogr. B. 745:2002;117-126.
34. Tsantili-Kakoulidou A, Panderi I, Piperaki S, Csizmadia F, Darvas F: Prediction of distribution coefficients from structure. Comparison of calculated and experimental data for various drugs. Eur J Drug Metab Pharmacokin 1999, 24:205-212. On World Wide Web URL: http://www.ahsystem.com/compudrug.html .
35. Lewis D.F.V. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human P450 substrate specificity and metabolism. Biochem. Pharmacol. 60:2000;293-306.
36. Box K, Bevan C, Comer J, Hill A, Allen R, Reynolds D: High throughput measurement of pKa values in a mixed-buffer linear pH gradient system. Anal Chem, in press.
37. Ishihama Y., Nakamura M., Miwa T., Kajima T., Asakawa N. A rapid method for pKa determination of drugs using pressure-assisted capillary electrophoresis with photodiode array detection in drug discovery. J. Pharm. Sci. 91:2002;933-942.
38. Jouravleva D: ACD/PhysChem: product overview. AAPS - ACD Users' Meeting 2002, Nov. Toronto http://www.acdlabs.com/publish/.
39. Masimirembwa C.M., Thompson R., Andersson T.B. In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. Comb. Chem. High Throughput Screen. 4:2001;245-263 The authors provided excellent comparisons and precautions for different high-throughput metabolic screening assays.
40. Li A.P. Screening for human ADME/Tox drug properties in drug discovery. Drug Disc. Today. 6:2001;357-366.
41. Xu R., Nemes C., Jenkins K.M., Rourick R.A., Kassel D.B., Liu C.Z.C. Application of parallel liquid chromatography/mass spectrometry for high throughput microsomal stability screening of compound libraries. J. Am. Soc. Mass. Spec. 13:2002;155-165.
42. Janiszewski J.S., Rogers K.J., Whalen K.M., Cole M.J., Liston T.E., Duchoslav E., Fouda H.G. A high-capacity LC/MS system for the bioanalysis of samples generated from plate-based metabolic screening. Anal. Chem. 73:2001;1495-1501 An innovative approach for increasing sensitivity and selectivity in high-throughput assays by using LC/MS/MS and unique automation.
43. Bertrand M., Jackson P., Walther B. Rapid assessment of drug metabolism in the drug discovery process. Eur. J. Pharm. Sci. 11(Suppl 2):2000;S61-S72.
44. Wang G., Hsieh Y., Lau Y.Y., Cheng K.-C., Ng K., Korfmacher W.A., White R.E. Semi-automated determination of plasma stability of drug discovery compounds using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. 780:2002;451-457.
45. Miller V.P., Stresser D.M., Blanchard A.P., Turner S., Crespi C.L. Fluorometric high-throughput screening for inhibitors of cytochrome P450. Annals New York Academy Sci. 919:2000;26-32.
46. Testino S.A. Jr., Patonay G. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 30:2003;1459-1467.
47. Moody G.C., Griffin S.J., Mather A.N., McGinnity D.F., Riley R.J. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica. 29:1999;53-75.
48. 50. J. Biomolec. Screening. 7:2002;373-382.
49. Nomeir A.A., Ruegg C., Shoemaker M., Favreau L.V., Palamanda J.R., Silber P., Lin C.C. Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. Drug Metab. Disp. 29:2001;748-753.
50. Stresser D.M., Blanchard A.P., Turner S.D., Erve J.C.L., Dandeneau A.A., Miller V.P., Crespi C.L. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab. Dispos. 28:2000;1440-1448.
51. Clark D.E. Computational methods for the prediction of ADME and toxicity. Adv. Drug Deliv. Rev. 54:2002;253-254 The entire issue (page 253-451) covers in silico methods for ADME/TOX predictions by a group of highly respected scientists.
52. Hay M.P., Gamage S.A., Kovacs M.S., Pruijn F.B., Anderson R.F., Patterson A.V., Wilson W.R., Brown J.M., Denny W.A. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J. Med. Chem. 46:2003;145-154.
53. MacKenzie A.R., Marchington A.P., Middleton D.S., Newman S.D., Jones B.C. Structure-activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)- 5-{2-[(3-substituted)-1-azetidinyl]ethyl}-2-piperidones. 1. Selective antagonists of the neurokinin-2 receptor. J. Med. Chem. 45:2002;5365-5377.
54. Regueiro-Ren A., Leavitt K., Kim S., Höfle G., Kiffe M., Gougoutas J.Z., DiMarco J.D., Lee F.Y.F., Fairchild C.R., Long B.H., Vite G.D. SAR and pH stability of cyano-substituted epothilones. Org. Lett. 4:2002;3815-3818.
55. Revesz L., Di Padova F.E., Buhl T., Feifel R., Gram H., Hiestand P., Manning U., Zimmerlin A.G. SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors. Bioorg. Med. Chem. Lett. 10:2000;1261-1264.